Literature DB >> 26922857

Apatinib in treatment of refractory gastric cancer.

Vicki Brower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26922857     DOI： 10.1016/S1470-2045(16)00138-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  14 in total

1.  Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.

Authors:  Zhe-Ling Chen; Andi Zhao; Pan Li; Mi Zhang; Jiao Yang; Lingxiao Zhang; Xiaoai Zhao; Jin Yang; Le Wang
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

Review 2.  Progress in the treatment of solid tumors with apatinib: a systematic review.

Authors:  Deze Zhao; Helei Hou; Xiaochun Zhang
Journal:  Onco Targets Ther       Date:  2018-07-19       Impact factor: 4.147

3.  Influence and mechanism of lung cavitation development on antiangiogenic therapy.

Authors:  Man Jiang; Chuantao Zhang; Dong Liu; Yongjie Wang; Hongmei Wang; Tianjun Li; Helei Hou; Na Zhou; Jingjuan Zhu; Hongying Lv; Chuanyu Zhang; Bingliang Fang; Xiaochun Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.

Authors:  Lihong Huang; Yongyue Wei; Sipeng Shen; Qianwen Shi; Jianling Bai; Jin Li; Shukui Qin; Hao Yu; Feng Chen
Journal:  Oncotarget       Date:  2017-04-25

5.  Bioinformatic analysis suggests that UGT2B15 activates the Hippo‑YAP signaling pathway leading to the pathogenesis of gastric cancer.

Authors:  Xuanmin Chen; Defeng Li; Nannan Wang; Meifeng Yang; Aijun Liao; Shuling Wang; Guangsheng Hu; Bing Zeng; Yuhong Yao; Diqun Liu; Han Liu; Weiwei Zhou; Weisheng Xiao; Peiyuan Li; Chen Ming; Song Ping; Pingfang Chen; Li Jing; Yu Bai; Jun Yao
Journal:  Oncol Rep       Date:  2018-07-26       Impact factor: 3.906

6.  NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer.

Authors:  Sifeng Hu; Fanmei Meng; Xiankun Yin; Changling Cao; Guangyong Zhang
Journal:  Biosci Rep       Date:  2019-05-17       Impact factor: 3.840

7.  Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients.

Authors:  Chunchao Zhu; Qin Yang; Jia Xu; Wenyi Zhao; Zizhen Zhang; Danhua Xu; Yeqian Zhang; Enhao Zhao; Gang Zhao
Journal:  J Transl Med       Date:  2019-04-03       Impact factor: 5.531

8.  The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.

Authors:  Jiangtao Yu; Ziwen Xu; Anyang Li; Jindi Zhang; Yi Wang; Hongqin Zhao; Haiyan Zhu
Journal:  Drug Des Devel Ther       Date:  2019-09-26       Impact factor: 4.162

9.  Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial.

Authors:  Ping Fang; Liqin Zhang; Xianru Zhang; Jiawen Yu; Jun Sun; Qi-An Jiang; Mingbao Zha; Anastasia P Nesterova; Hongbao Cao
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

10.  Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.

Authors:  Lei Wang; Changyong Yang; Chengying Xie; Jiahua Jiang; Mingzhao Gao; Li Fu; Yun Li; Xubin Bao; Haoyu Fu; Liguang Lou
Journal:  Cancer Sci       Date:  2019-02-19       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.